Sponsored Links
-->

Monday, May 7, 2018

Prostate Cancer Treatment - SCCA Proton Therapy Center
src: www.sccaprotontherapy.com

In the field of medical procedures, Proton therapy, or proton beam therapy is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often in the treatment of cancer. The chief advantage of proton therapy over other types of external beam radiotherapy is that as a charged particle the dose is deposited over a narrow range and there is minimal exit dose.


Video Proton therapy



Description

Proton therapy is a type of external beam radiotherapy that uses ionizing radiation. In proton therapy, medical personnel use a particle accelerator to target a tumor with a beam of protons. These charged particles damage the DNA of cells, ultimately killing them or stopping their reproduction. Cancerous cells are particularly vulnerable to attacks on DNA because of their high rate of division and their reduced abilities to repair DNA damage. Some cancers with specific defects in DNA repair may be more sensitive to proton radiation.

Because of their relatively large mass, protons have little lateral side scatter in the tissue; the beam does not broaden much, stays focused on the tumor shape and delivers only low-dose side effects to surrounding tissue. All protons of a given energy have a certain penetration range; very few protons penetrate beyond that distance. Furthermore, the dose delivered to tissue is maximized only over the last few millimeters of the particle's range; this maximum is called the Bragg peak, often referred to as the SOBP.

To treat tumors at greater depths, the proton accelerator must produce a beam with higher energy, typically given in eV or electron volts. Accelerators used for proton therapy typically produce protons with energies in the range of 70 to 250 MeV. Adjusting proton energy during the treatment maximizes the cell damage the proton beam causes within the tumor. Tissue closer to the surface of the body than the tumor receives reduced radiation, and therefore reduced damage. Tissues deeper in the body receive very few protons, so the dosage becomes immeasurably small.

In most treatments, protons of different energies with Bragg peaks at different depths are applied to treat the entire tumor. These Bragg peaks are shown as thin blue lines in the figure to the right. The total radiation dosage of the protons is called the spread-out Bragg peak (SOBP), shown as a heavy dashed blue line in figure to the right. It is important to understand that, while tissues behind (or deeper than) the tumor receive almost no radiation from proton therapy, the tissues in front of (shallower than) the tumor receive radiation dosage based on the SOBP.

Equipment

Most installed proton therapy systems utilise isochronous cyclotrons. Cyclotrons are considered simple to operate, reliable and can be made compact, especially with the use of superconducting magnets. Synchrotrons can also be used, with the advantage of easier production at varying energies. Linear accelerators, as used for photon radiation therapy, are becoming commercially available as problems of size and cost are resolved.


Maps Proton therapy



History

The first suggestion that energetic protons could be an effective treatment method was made by Robert R. Wilson in a paper published in 1946 while he was involved in the design of the Harvard Cyclotron Laboratory (HCL). The first treatments were performed with particle accelerators built for physics research, notably Berkeley Radiation Laboratory in 1954 and at Uppsala in Sweden in 1957. In 1961, a collaboration began between HCL and the Massachusetts General Hospital (MGH) to pursue proton therapy. Over the next 41 years, this program refined and expanded these techniques while treating 9,116 patients before the cyclotron was shut down in 2002. The world's first hospital-based proton therapy center was a low energy cyclotron centre for ocular tumours at the Clatterbridge Centre for Oncology in the UK, opened in 1989, followed in 1990 at the Loma Linda University Medical Center (LLUMC) in Loma Linda, California. Later, The Northeast Proton Therapy Center at Massachusetts General Hospital was brought online, and the HCL treatment program was transferred to it during 2001 and 2002. By 2010 these facilities were joined by an additional seven regional hospital-based proton therapy centers in the United States alone, and many more worldwide.


Proton therapy - Wikipedia
src: upload.wikimedia.org


Application

Physicians use protons to treat conditions in two broad categories:

  • Disease sites that respond well to higher doses of radiation, i.e., dose escalation. In some instances, dose escalation has demonstrated a higher probability of "cure" (i.e., local control) than conventional radiotherapy. These include, among others, uveal melanoma (ocular tumors), skull base and paraspinal tumors (chondrosarcoma and chordoma), and unresectable sarcomas. In all these cases proton therapy achieves significant improvements in the probability of local control over conventional radiotherapy. In treatment of ocular tumors, proton therapy also has high rates of maintaining the natural eye.
  • Treatments where proton therapy's increased precision reduces unwanted side effects by lessening the dose to normal tissue. In these cases, the tumor dose is the same as in conventional therapy, so there is no expectation of an increased probability of curing the disease. Instead, the emphasis is on reducing the integral dose to normal tissue, thus reducing unwanted effects.

Two prominent examples are pediatric neoplasms (such as medulloblastoma) and prostate cancer.

Pediatric treatments

Irreversible, long-term side effects of conventional radiation therapy for pediatric cancers have been well documented and include growth disorders, neurocognitive toxicity, ototoxicity with subsequent effects on learning and language development, renal, endocrine and gonadal dysfunctions. Radiation-induced secondary malignancy is another very serious adverse effect that has been reported. As there is no exit dose when using proton radiation therapy, the dose to surrounding normal tissues can be significantly limited, reducing the acute toxicity which positively impacts the risk for these long-term side effects. Cancers requiring craniospinal irradiation, for example, benefit from the absence of exit dose with proton therapy: dose to the heart, mediastinum, bowel, bladder and other tissues anterior to the vertebrae is eliminated, resulting in a reduction of acute thoracic, gastrointestinal and bladder side effects.

Prostate cancer

In prostate cancer cases, the issue is less clear. Some published studies found a reduction in long term rectal and genito-urinary damage when treating with protons rather than photons (meaning X-ray or gamma ray therapy). Others showed a small difference, limited to cases where the prostate is particularly close to certain anatomical structures. The relatively small improvement found may be the result of inconsistent patient set-up and internal organ movement during treatment, which offsets most of the advantage of increased precision. One source suggests that dose errors around 20% can result from motion errors of just 2.5 mm (0.098 in). and another that prostate motion is between 5-10 mm (0.20-0.39 in).

However, the number of cases of prostate cancer diagnosed each year far exceeds those of the other diseases referred to above, and this has led some, but not all, facilities to devote a majority of their treatment slots to prostate treatments. For example, two hospital facilities devote roughly 65% and 50% of their proton treatment capacity to prostate cancer, while a third devotes only 7.1%.

Overall worldwide numbers are hard to compile, but one example states that in 2003 roughly 26% of proton therapy treatments worldwide were for prostate cancer.

Eye tumors

Proton therapy for ocular (eye) tumors is a special case since this treatment requires only comparatively low energy protons (about 70 MeV). Owing to this low energy requirement, some particle therapy centers only treat ocular tumors. Proton, or more generally, hadron therapy of tissue close to the eye affords sophisticated methods to assess the alignment of the eye that can vary significantly from other patient position verification approaches in image guided particle therapy. Position verification and correction must ensure that the radiation spares sensitive tissue like the optic nerve to preserve the patient's vision.

Head and neck tumors

Proton particles do not deposit exit dose, which allows proton therapy to spare normal tissues distal to the tumor target. This is particularly useful for treating head and neck tumors because of the anatomic constraints encountered in nearly all cancers in this region. The dosimetric advantage unique to proton therapy translates into toxicity reduction. For recurrent head and neck cancer requiring reirradiation, proton therapy is able to maximize a focused dose of radiation to the tumor while minimizing dose to surrounding tissues which results in a minimal acute toxicity profile, even in patients who have received multiple prior courses of radiotherapy.

Lymphoma (Tumors of lymphatic tissue)

Although chemotherapy is the primary treatment for patients with lymphoma, consolidative radiation is often used in Hodgkin lymphoma and aggressive non-Hodgkin lymphoma, while definitive treatment with radiation alone is used in a small fraction of lymphoma patients. Unfortunately, treatment-related toxicities caused by chemotherapy agents and radiation exposure to healthy tissues are major concerns for lymphoma survivors. Advanced radiation therapy technologies such as proton therapy may offer significant and clinically relevant advantages such as sparing important organs at risk and decreasing the risk for late normal tissue damage while still achieving the primary goal of disease control. This is especially important for lymphoma patients who are being treated with curative intent and have long life expectancies following therapy.

Gastrointestinal malignancy

An increasing amount of data reported has shown that proton therapy has great potential to increase therapeutic tolerance for patients with GI malignancies. The possibility of decreasing radiation dose to organs at risk may also help facilitate chemotherapy dose escalation or allow for new chemotherapy combinations. Proton therapy will play a decisive role in the context of ongoing intensified combined modality treatments for GI cancers. The following review presents the benefits of proton therapy in treating hepatocellular carcinoma, pancreatic cancer and esophageal cancer.


Georgetown Lombardi Cancer Center | Proton Therapy Lab | Forrester ...
src: gnaoqghq0g-flywheel.netdna-ssl.com


Comparison with other treatments

The issue of when, whether, and how best to apply this technology is controversial. As of 2012 there have been no controlled trials to demonstrate that proton therapy yields improved survival or other clinical outcomes (including impotence in prostate cancer) compared to other types of radiation therapy, although a five-year study of prostate cancer is underway at Massachusetts General Hospital.

Proton therapy is far more expensive than conventional therapy. As of 2012 proton therapy required a very large capital investment (from US$100M to more than $180M).

Preliminary results from a 2009 study, including high-dose treatments, showed very few side effects.

NHS Choices has stated:

We cannot say with any conviction that proton beam therapy is "better" overall than radiotherapy. (...) Some overseas clinics providing proton beam therapy heavily market their services to parents who are understandably desperate to get treatment for their children. Proton beam therapy can be very costly and it is not clear whether all children treated privately abroad are treated appropriately.

X-ray radiotherapy

The figure at the right of the page shows how beams of X-rays (IMRT; left frame) and beams of protons (right frame), of different energies, penetrate human tissue. A tumor with a sizable thickness is covered by the IMRT spread out Bragg peak (SOBP) shown as the red lined distribution in the figure. The SOBP is an overlap of several pristine Bragg peaks (blue lines) at staggered depths.

Megavoltage X-ray therapy has less "skin scarring potential" than proton therapy: X-ray radiation at the skin, and at very small depths, is lower than for proton therapy. One study estimates that passively scattered proton fields have a slightly higher entrance dose at the skin (~75%) compared to therapeutic megavoltage (MeV) photon beams (~60%). X-ray radiation dose falls off gradually, unnecessarily damaging tissue deeper in the body and damaging the skin and surface tissue opposite the beam entrance. The differences between the two methods depends on the:

  • Width of the SOBP
  • Depth of the tumor
  • Number of beams that treat the tumor

The X-ray advantage of reduced damage to skin at the entrance is partially counteracted by damage to skin at the exit point.

Since X-ray treatments are usually done with multiple exposures from opposite sides, each section of skin is exposed to both entering and exiting X-rays. In proton therapy, skin exposure at the entrance point is higher, but tissues on the opposite side of the body to the tumor receive no radiation. Thus, X-ray therapy causes slightly less damage to the skin and surface tissues, and proton therapy causes less damage to deeper tissues in front of and beyond the target.

An important consideration in comparing these treatments is whether the equipment delivers protons via the scattering method (historically, the most common) or a spot scanning method. Spot scanning can adjust the width of the SOBP on a spot-by-spot basis, which reduces the volume of normal (healthy) tissue inside the high dose region. Also, spot scanning allows for intensity modulated proton therapy (IMPT), which determines individual spot intensities using an optimization algorithm that lets the user balance the competing goals of irradiating tumors while sparing normal tissue. Spot scanning availability depends on the machine and the institution. Spot scanning is more commonly known as pencil-beam scanning and is available on IBA, Hitachi, Mevion (known as hyperscan and not US FDA approved as of 2015) and Varian.

Surgery

Physicians base the decision to use surgery or proton therapy (or any radiation therapy) on the tumor type, stage, and location. In some instances, surgery is superior (such as cutaneous melanoma), in some instances radiation is superior (such as skull base chondrosarcoma), and in some instances they are comparable (for example, prostate cancer). In some instances, they are used together (e.g., rectal cancer or early stage breast cancer). The benefit of external beam proton radiation lies in the dosimetric difference from external beam X-ray radiation and brachytherapy in cases where the use of radiation therapy is already indicated, rather than as a direct competition with surgery. However, in the case of prostate cancer, the most common indication for proton beam therapy, no clinical study directly comparing proton therapy to surgery, brachytherapy, or other treatments has shown any clinical benefit for proton beam therapy. Indeed, the largest study to date showed that IMRT compared with proton therapy was associated with less gastrointestinal morbidity.


IBA video - The workflow of patient treatment in a proton center ...
src: i.ytimg.com


Side effects and risks

Proton therapy is a type of external beam radiotherapy, and shares risks and side effects of other forms of radiation therapy. However the dose outside of the treatment region can be significantly less for deep-tissue tumors than X-ray therapy, because proton therapy takes full advantage of the Bragg peak. Proton therapy has been in use for over 40 years, and is a mature treatment technology. However, as with all medical knowledge, understanding of the interaction of radiation (proton, X-ray, etc.) with tumor and normal tissue is still imperfect.


Reining in Costs and Ensuring Feasibility of Proton Beam Therapy ...
src: www.iaea.org


Costs

Historically, proton therapy has been expensive. An analysis published in 2003 determined the relative cost of proton therapy is approximately 2.4 times that of X-ray therapies. However, newer, more compact proton beam sources can be 4-5 times cheaper and offer more accurate three-dimensional targeting. Thus the cost is expected to reduce as better proton technology becomes more widely available. An analysis published in 2005 determined that the cost of proton therapy is not unrealistic and should not be the reason for denying patients access to the technology. In some clinical situations, proton beam therapy is clearly superior to the alternatives.

A study in 2007 expressed concerns about the effectiveness of proton therapy for treating prostate cancer, but with the advent of new developments in the technology, such as improved scanning techniques and more precise dose delivery ('pencil beam scanning'), this situation may change considerably. Amitabh Chandra, a health economist at Harvard University, stated, "Proton-beam therapy is like the death star of American medical technology... It's a metaphor for all the problems we have in American medicine." However, another study has shown that proton therapy in fact brings cost savings. The advent of second generation, and much less expensive, proton therapy equipment which emerged by 2012 may change opinions.


IBA Proton Therapy BRoll EQUIPMENT - YouTube
src: i.ytimg.com


Treatment centers

As of July 2017, there are over 75 particle therapy facilities worldwide, with at least 41 others under construction. As of the end of 2015 more than 154,203 patients had been treated.

One hindrance to universal use of the proton in cancer treatment is the size and cost of the cyclotron or synchrotron equipment necessary. Several industrial teams are working on development of comparatively small accelerator systems to deliver the proton therapy to patients. Among the technologies being investigated are superconducting synchrocyclotrons (also known as FM Cyclotrons), ultra-compact synchrotrons, dielectric wall accelerators, and linear particle accelerators.

United States

Proton treatment centers in the United States as of 2017 (in chronological order of first treatment date) include:

The Indiana University Health Proton Therapy Center in Bloomington, Indiana opened in 2004 and ceased operations in 2014.

Outside the USA


Provision CARES Proton Therapy - Nashville Archives - Provision ...
src: provisionhealthcare.com


United Kingdom

In 2013 the British government announced that £250 million had been budgeted to establish two centers for advanced radiotherapy, to open in 2018 at the Christie Hospital NHS Foundation Trust in Manchester and University College London Hospitals NHS Foundation Trust. These would offer high-energy proton therapy, currently unavailable in the UK, as well as other types of advanced radiotherapy, including intensity-modulated radiotherapy (IMRT) and image-guided radiotherapy (IGRT). In 2014, only low-energy proton therapy was available in the UK, at the Clatterbridge Cancer Centre NHS Foundation Trust in Merseyside. But NHS England has paid to have suitable cases treated abroad, mostly in the US. Such cases have risen from 18 in 2008 to 122 in 2013, 99 of whom were children. The cost to the National Health Service averaged around £100,000 per case.

In January 2015, it was announced the UK would get its first high energy proton beam therapy centre a year earlier than expected. A company named Advanced Oncotherapy signed a deal with Howard de Walden Estate to install a machine in Harley Street, the heart of private medicine in London, to be ready by 2017. The company promises that its use of a linear accelerator allows for facilities one-third smaller and one-fifth the cost of facilities based on existing cyclotron designs.

Proton Partners International is developing three centres in Newport, Wales, Bomarsund, Northumberland, and Reading, Berkshire which are expected to open in 2017.


pencil beam scanning IBA Proton Therapy - YouTube
src: i.ytimg.com


See also

  • Particle therapy
  • Charged particle therapy
  • Hadron
  • Microbeam
  • Fast neutron therapy
  • Boron neutron capture therapy
  • Linear energy transfer
  • Electromagnetic radiation and health
  • Dosimetry
  • Ionizing radiation
  • List of oncology-related terms

Proton Therapy - Robust Planning | RaySearch Laboratories
src: www.raysearchlabs.com


References

77 Bortfeld, Thomas R. and Jay S. Loeffler (2017) Three ways to make proton therapy affordable. Nature 549, 451-453 (28 September 2017) doi:10.1038/549451a


How does proton therapy work? See the difference of proton and ...
src: i.ytimg.com


Further reading

  • Greco C.; Wolden S. (Apr 2007). "Current status of radiotherapy with proton and light ion beams". Cancer. 109 (7): 1227-38. doi:10.1002/cncr.22542. PMID 17326046. 
  • "Use of Protons for Radiotherapy", A.M. Koehler, Proc. of the Symposium on Pion and Proton Radiotherapy, Nat. Accelerator Lab., (1971).
  • A.M. Koehler, W.M. Preston, "Protons in Radiation Therapy: comparative Dose Distributions for Protons, Photons and Electrons Radiology 104(1):191-195 (1972).
  • "Bragg Peak Proton Radiosurgery for Arteriovenous Malformation of the Brain" R.N. Kjelberg, presented at First Int. Seminar on the Use of Proton Beams in Radiation Therapy, Moskow (1977).
  • Austin-Seymor, M.J. Munzenrider, et al. "Fractionated Proton Radiation Therapy of Cranial and Intracrainial Tumors" Am. J. of Clinical Oncology 13(4):327-330 (1990).
  • "Proton Radiotherapy", Hartford, Zietman, et al. in Radiotheraputic Management of Carcinoma of the Prostate, A. D'Amico and G.E. Hanks. London, UK, Arnold Publishers: 61-72 (1999).

University College London Hospitals รข€
src: www.steffian.com


External links

  • Proton therapy--MedlinePlus Medical Encyclopedia
  • Proton Therapy
  • "Proton therapy is coming to the UK, but what does it mean for patients?", Arney, Kat, Science blog, Cancer Research UK, 16 September 2013
  • Proton Therapy in Korea

Source of the article : Wikipedia

Comments
0 Comments